| Title |
Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
|
|---|---|
| Published in |
BMC Cancer, December 2012
|
| DOI | 10.1186/1471-2407-12-612 |
| Pubmed ID | |
| Authors |
Elina Jokinen, Niina Laurila, Jussi P Koivunen |
| Abstract |
PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are thought to be the central transducers of oncogenic signals in solid malignancies, and there has been a lot of enthusiasm for developing inhibitors of these pathways for cancer therapy. Some preclinical models have suggested that combining inhibitors of both parallel pathways may be more efficacious, but it remains unknown whether dual inhibition with high enough concentrations of the drugs to achieve meaningful target inhibition is tolerable in a clinical setting. Furthermore, the predictive factors for dual inhibition are unknown. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 24% |
| Student > Master | 11 | 20% |
| Student > Ph. D. Student | 10 | 18% |
| Student > Bachelor | 5 | 9% |
| Professor > Associate Professor | 4 | 7% |
| Other | 6 | 11% |
| Unknown | 6 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 17 | 31% |
| Medicine and Dentistry | 14 | 25% |
| Biochemistry, Genetics and Molecular Biology | 8 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Chemistry | 2 | 4% |
| Other | 2 | 4% |
| Unknown | 7 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2012.
All research outputs
#15,258,711
of 22,689,790 outputs
Outputs from BMC Cancer
#4,099
of 8,250 outputs
Outputs of similar age
#181,137
of 280,032 outputs
Outputs of similar age from BMC Cancer
#61
of 115 outputs
Altmetric has tracked 22,689,790 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,250 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,032 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 115 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.